[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malignancies-multiple\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malignancies-multiple":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100632347","remote-vital-sign-monitoring-in-palliative-care-patients-using-a-wearable-ecg-monitor-100632347",false,"NCT07512505","Remote Vital Sign Monitoring in Palliative Care Patients Using a Wearable ECG Monitor","Remote Vital Sign Monitoring in Palliative Care - VITAL-PC","VITAL-PC","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Primary diagnosis of malignant disease\n* Admitted for end-of-life care (or focus of care changed to end-of-life care)\n* Estimated prognosis \\\u003C 14 days\n\nExclusion Criteria:\n\n* Primary diagnosis of non-malignant disease\n* Inability to provide informed consent\n* Contraindications to use of biosensor adhesive patch (e.g. chest wall skin problem, allergy to adhesive)","ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","OBSERVATIONAL","The goal of this study is the assess the use of remote monitoring of vital signs using commercially available medical devices in patients with advanced cancer admitted to a hospice inpatient unit for end-of-life care.\n\nThe objectives of the study are:\n\n1. could remote monitoring of vital signs improve patient care through the earlier identification of infections and other (potentially reversible) problems;\n2. could remote monitoring of vital signs improve the accuracy of our estimates about how long a person has to live; and c) determine the relationship between complaints of pain \u002F other symptoms and vital signs.",[25,26,27,28],"Cancer","Malignancies Multiple","Terminal Care","Hospice",[30,31,32,27,33,34,28,25],"Remote Monitoring","Vital Sign Monitoring","End-of-life care","Remote monitoring of vital signs in palliative care","Palliative care","RECRUITING","2026-03-30",{"date":38,"type":39},"2026-04-06","ACTUAL",{"date":41,"type":39},"2025-11-06",{"date":43,"type":21},"2027-10-01",{"name":45,"class":46},"Our Lady's Hospice and Care Services","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":47},"100282788","phase-1-anti-pd-1-antibody-alone-or-in-combination-with-decitabinechemotherapy-in-relapsed-or-refractory-malignancies-100282788","NCT02961101","Anti-PD-1 Antibody Alone or in Combination With Decitabine\u002FChemotherapy in Relapsed or Refractory Malignancies","Anti-PD-1 Antibody Alone or in Combination With Low-dose Decitabine and\u002For Chemotherapy in Relapsed or Refractory Malignancies: an Open-label Phase I\u002FII Trial","Inclusion Criteria:\n\n1. Subjects must have histological confirmation of relapsed or refractory malignancies,including Non-Hodgkin'lymphoma, Hodgkin'lymphoma, gastrointestinal cancers, hepatocellular carcinoma, breast cancer, ovarian cancer or lung cancer or renal-cell cancer or pancreatic cancer or bile duct cancer.\n2. 12 to 75 years of age.\n3. ECOG performance of less than 2.\n4. Life expectancy of at least 3 months.\n5. Subjects with lymphoma must have at least one measureable lesion \\>1 cm as defined by lymphoma response criteria; with solid tumors must have at least one measureable lesion \\>1 cm per RECIST1.1.\n6. Subjects must have received at least two prior chemotherapy regimen, and must be off therapy for at least 4 weeks prior to Day 1. Subjects with autologous hematopoietic stem-cell transplantation are eligible which must be more than 3 months.\n7. Subjects must have adequate bone marrow, live, renal, lung and heart functions.\n\n   1. Absolute neutrophil count greater than or equal to 1,000\u002FμL.\n   2. Platelet count greater than or equal to 70,000\u002FµL.\n   3. Serum bilirubin level less than or equal to 1.5 x upper limits of normal (ULN).\n   4. Serum creatinine less than or equal to 1.5 x ULN.\n   5. Alanine aminotransferase \\[ALT or SGPT\\] and aspartate aminotransferase \\[AST or SGOT\\] less than or equal to 2.5 x ULN.\n\nExclusion Criteria:\n\n1. Subjects with any autoimmune disease or history of syndrome that requires corticosteroids or immunosuppressive medications.\n2. Serious uncontrolled medical disorders or active infections, pulmonary and intestinal infection especially.\n3. Active alimentary tract hemorrhage or history of alimentary tract hemorrhage in 1 month .\n4. Prior organ allograft.\n5. Women who are pregnant or breastfeeding.\n6. Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.","12 Years","75 Years",{"count":58,"type":21},250,"INTERVENTIONAL",[61,62],"PHASE1","PHASE2","The purpose of this study is to assess the feasibility, safety, and efficacy of anti-PD-1 antibody alone or in combination with low-dose decitabine in patients with relapsed or refractory malignancies, including Non-Hodgkin'lymphoma, Hodgkin'lymphoma, gastrointestinal cancers, hepatocellular carcinoma, breast cancer, ovarian cancer or lung cancer or renal-cell cancer or pancreatic cancer or bile duct cancer.",[26],[66,67,68,69,70],"relapsed or refractory","malignancies","decitabine","anti-PD-1 antibody","chemotherapy","2026-01-21",{"date":73,"type":39},"2026-01-22",{"date":75,"type":4},"2016-05",{"date":77,"type":21},"2026-05",{"name":79,"class":46},"Han weidong",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":89,"conditions":90,"keywords":99,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":118},"100374121","canadian-cancers-with-rare-molecular-alterations-carma---basket-real-world-observational-study-bros-100374121","NCT04151342","CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)","CARMA-BROS","Inclusion Criteria:\n\n* Patients ≥ 18 years at cancer diagnosis\n* Diagnosed with malignant tumour(s) with molecular testing completed that identified rare molecular alterations\n* Accessible\u002Favailable molecular testing reports\u002Fdocumentation to confirm type(s) of molecular alteration(s) (resulting from the conduct of polymerase chain reaction \\[PCR\\] based next generation sequencing \\[NGS\\], immunohistochemistry \\[IHC\\], fluorescence in situ hybridization \\[FISH\\], liquid biopsy)\n* Canadian resident received follow-up for cancer care in Canada or is currently receiving\u002Fplanning follow-up for cancer care to occur in Canada at time of enrollment\n\nExclusion Criteria:\n\n* Previous refusal of the deceased patient, when living, to enroll in this study or patient approached for this study is unable to provide informed consent",{"count":88,"type":21},5500,"This study will collect data on Canadian cancer patients that have uncommon\u002Frare changes in their tumours, such as alterations\u002Frearrangements in the genetic material inside cells - known as deoxyribonucleic acid, or DNA, which acts as a map and gives directions to the cells on how to make other substances the body needs - because some of these changes have been found to respond to different drugs that help to stop the cancer. These rare changes occur in genes such as but not limited to ALK, EGFR, ROS1, BRAF, and NTRK which have targeted drugs in a family known as tyrosine kinase inhibitors (TKIs), and KRAS G12C mutation, which now has a targeted inhibitor drug therapy for patients with non small cell lung cancer (NSCLC). The goals for the study are to compare the natural history of such cancers and the treatment outcomes, including toxicities and patient-reported outcomes, for the different therapies.",[25,26,91,92,93,94,95,96,97,98],"Malignant Solid Tumor","Cancer, Therapy-Related","Molecular Sequence Variation","Genetic Alteration","Gene Fusion","Receptor Tyrosine Kinase Gene Mutation","RTK Family Gene Mutation","Ras (Kras or Nras) Gene Mutation",[100,101,102,103,104,105,106,107,108],"observational study","cancer","cancer therapies","molecular alterations","real-world evidence","real-world data","tyrosine kinase inhibitors","ambispective","ras GTPase inhibitors","2025-11-25",{"date":111,"type":39},"2025-12-03",{"date":113,"type":39},"2020-01-17",{"date":115,"type":21},"2029-12",{"name":117,"class":46},"University Health Network, Toronto",27]